Studies with molecular and immunological techniques identified and mapped the transcript encoding glycoprotein D (gD) of equine herpesvirus 1 KyA, as well as two continuous gD antigenic determinants. Three mRNA species of 5.5, 3.8, and 1.7 kb overlap the gD open reading frame and are transcribed from the DNA strand encoding gD. Northern (RNA) blot hybridization with both DNA clones and riboprobes, as well as S1 nuclease analyses, showed the 3.8-kb mRNA to encode gD and to be synthesized as a late (beta-gamma) transcript. The 3.8-kb gD mRNA initiates within the Us segment 91 and 34 nucleotides downstream of the CCAAT and TATA elements, respectively, and encodes a potential polypeptide of 392 amino acids. The termination site of this transcript maps within the terminal repeat at a site also used by the 5.5-kb mRNA and the IR6-encoded 1.2-kb mRNA, such that these three transcripts form a 3'-coterminal nested set. The extended size (2,250 nucleotides) of the 3' untranslated region of the gD transcript and its termination within the terminal repeat may result from the deletion of 3,859 bp, which eliminates two consensus polyadenylation signals downstream of the gD open reading frame of EHV-1 KyA. Use of antisera to synthetic peptides of 19 amino acids (residues 4 to 22) and 20 amino acids (residues 267 to 285) in Western immunoblot analyses revealed that gD is present in EHV-1 virions as a 55-kDa polypeptide. In addition, these antisera detected the 55-kDa protein as well as 58-and 47-kDa polypeptides in infected-cell extracts at late times of infection. Residues 4 to 22 make up a continuous neutralizing epitope of gD, since incubation of equine herpesvirus 1 with the anti-19-mer serum prior to infection results in reduced numbers of plaques and reduced levels of vims-encoded thymidine kinase. Complement is not required for neutralization mediated by the anti-19-mer serum.
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DNA sequence analysis of the unique short sequence (Us) of the short region of the equine herpesvirus 1 (EHV-1) genome has revealed the presence of nine open reading frames (ORFs) (1, 3, 9, 16, 19, 20) . Five of these ORFs encode potential glycoproteins, four being homologs of herpes simplex virus type 1 (HSV-1) gG (9) , gD (1, 16, 19) , gI, and gE (1, 16) . The EUS4 ORF specifies a potential glycoprotein that has no counterpart in any herpesvirus sequenced to date (9) . With the single exception of varicellazoster virus (10) , the alphaherpesviruses HSV-1 (37, 64) , pseudorabies virus (50) , and bovine herpesvirus type 1 (62) and the gammaherpesvirus Marek's disease virus (55, 56) encode a gD which appears to mediate key events in the early phase of the replication cycle (60) . Notable among the gD polypeptides is the conservation of cysteine residues located within the central portion of the surface-exposed domain. Studies of HSV-1 gD have indicated that these cysteines form intramolecular disulfide bonds that are essential for the structural integrity of the protein (34, 67) . Studies to elucidate the antigenic structure of HSV-1 gD revealed that the location of discontinuous epitopes correlates with the placement of cysteine residues, indicating that the central domain of gD possesses a highly ordered structure (39) . In contrast, most continuous epitopes lie near the amino terminus and within the carboxyl one-third of HSV-1 gD (39) .
Previous studies have implicated HSV-1 gD in virus penetration since anti-HSV-1 gD antibodies neutralize infectivity (7, 13-15, 21, 28, 38) , retard fusion of infected cells (4, 28, 38, 41) , and inhibit penetration without affecting adsorp-* Corresponding author.
tion (21, 28, 41) . Direct evidence for the participation of gD in penetration was obtained by the demonstration that HSV-1 virions that lack gD could attach to cells but were noninfectious as a result of a block in virus entry (31, 33) . Similarly, the HSV-1 gD homologs of pseudorabies virus .(gpSO) and bovine herpesvirus type 1 (gIV) were shown to be essential gene products that are involved in the process of penetration (11, 18, 47, 53) . Recently, Muggeridge et al. (40) and Feenstra et al. (17) , through the analysis of a series of HSV-1 gD deletion mutations, identified a domain that is essential for infectivity.
The HSV-1 gD gene is transcribed as a 3.0-kb mRNA that is one of three transcripts of a 3'-coterminal nested set mapping within the Us of HSV-1 (29, 37, 54) . The gD transcript and polypeptide can be detected as early as 2 h after infection but do not reach maximal levels until after the onset of viral DNA replication; therefore, the gD gene has been assigned to the beta-gamma kinetic class (8, 29, 32, 46, 58) .
In contrast to the extensive knowledge of HSV-1 gD, little is known about the nature of EHV-1 gD. In the present study, the gD gene of EHV-1 KyA strain was shown to be transcribed as a 3.8-kb mRNA that belongs to the betagamma kinetic class. This finding agrees with our recent observations that gD is not regulated as an early gene since the requirements for transactivation of the EHV-1 gD promoter differ from those of the early EHV-1 thymidine kinase (TK) promoter (59) . The Importantly, the synthetic peptide composed of residues 4 through 22 elicits the production of complementindependent neutralizing antibodies, as is the case for the analogous residues of HSV-1 gD (7, 13, 38) . These data suggest that EHV-1 gD, like its HSV-1 counterpart, plays a role in penetration.
MATERIALS AND METHODS
Virus and cell culture. The EHV-1 Kentucky A (KyA) strain was serially propagated by infection of LM cell suspension cultures at low multiplicity of infection (0.05 PFU per cell [42] ). Virus infectivity was quantitated by plaque titration (42, 48 Strand-specific riboprobes were generated by using the Riboprobe Gemini System (Promega, Madison, Wis.). EHV-1 DNA restriction fragments cloned into the pGEM-3Z plasmid vector were restriction digested so that runoff transcripts could be synthesized from either the T7 or SP6 phage promoters (27) . Linear (30) , was used to predict highly immunogenic regions of EHV-1 gD from the amino acid sequence (19) . Two Virus neutralization assays. Neutralization of EHV-1 infectivity by gD-specific sera was monitored by assaying virus-specific TK activity. LM cell monolayers in 96-well microtiter plates were infected with virus which had been preincubated for 1 h with serum (preimmune or peptidespecific serum diluted 1/160 with phosphate-buffered saline). Three separate monolayers were infected at each multiplicity of infection ranging from 0 (mock infected) to 10, and the infected cells were harvested 16 h after infection. The method of Wolcott and Colacino (68) was used to monitor EHV-1-specific TK activity in infected-cell lysates. The protocol is based on the selective phosphorylation of 5'-[12'I]iodo-2'-deoxycytidine (2,000 Ci/mmol; Dupont NEN) followed by lanthanum chloride precipitation of phosphorylated compounds. TK activity is represented by the radioactivity present in the precipitate. Each determination of TK activity represents the average of three independent TK assays performed for each cell lysate.
Plaque reduction assays were also used to assess EHV-1 neutralization. To inactivate complement, preimmune or peptide-specific sera were incubated for 1 h at 56°C. Virus inoculum containing 3,000 PFU was incubated with serial dilutions of preimmune or peptide-specific sera, and the virus-antibody mixtures were incubated at 37°C for 1 h.
Virus infectivity was measured by plaque assay in LM cell monolayers (48) . Neutralization activities represent the average of three infected cultures and were calculated as the percentage of plaques that had been neutralized.
RESULTS
Identification and kinetic class of transcripts overlapping the EHV-1 gD ORF. To identify and characterize the mRNA species transcribed from the gD coding sequences, we performed Northern blot hybridization analyses with RNA isolated from EHV-1-infected LM cells. Clone pSZ-4, which contains the entire gD ORF (Fig. 1) , (19) (3) . As predicted, the 1.2-kb mRNA was also detected within the TR. ods). No hybridization signal was observed with mockinfected RNA (Fig. 2, lane 1 synthesis [6] ). The 5.5-and 1.7-kb mRNAs were not detected when viral DNA synthesis was inhibited with PAA but were detected in unblocked infections at 8 h postinfection, suggesting that these mRNAs belong to the gamma kinetic class.
Direction of transcription and fine mapping of the 5.5-, 3.8-, and 1.7-kb mRNAs. To determine which of the three overlapping mRNA species encodes gD, we conducted Si nuclease analyses as well as Northern blot hybridization experiments with riboprobes and a series of cloned fragments containing Us sequences. To generate riboprobes, clone pCF6 was used since it contains potential cis-regulatory elements for gD expression and sequences encoding the amino-terminal portion of the gD protein ( Fig. 1) (19) . Clone pCF6 was inserted into pGEM-3Z such that transcription from the T7 phage promoter yielded a riboprobe complementary to the gD coding strand while transcription from the SP6 phage promoter yielded a riboprobe complementary to the noncoding strand of gD. As shown in Fig. 3A (lane 4) , the T7-generated riboprobe hybridized to all three mRNAs (5.5, 3.8, and 1.7 kb). The hybridization to the 5.5-and 3.8-kb mRNAs was readily apparent by 15 min of autoradiographic exposure, whereas the 1.7-kb mRNA required a longer exposure for its detection. The SP6-generated riboprobe failed to hybridize to any of the three mRNAs (Fig. 3A , lane 2), even after prolonged periods of autoradiographic exposure. These results demonstrate that the 5.5-, 3.8-, and 1.7-kb mRNAs are transcribed from the gD coding strand.
To determine the map location of each mRNA, we performed Northern blot analyses with a series of contiguous clones containing Us and/or terminal repeat (TR) sequences as probes (Fig. 1) . Clones pCF3, pCF5, pCF6, and pCF7 ( Fig. 1) , which contain only Us sequences, hybridized to mRNAs of 5.5, 3.8, 2.9, and 1.7 kb (Fig. 3B) . The 2.9-kb mRNA terminates within clone pCF3 since this mRNA was not detected with clone pCF5. The 1.7-kb mRNA was detected with probe pCF6 but not with pCF7, indicating that the 3' terminus of the 1.7-kb mRNA lies within clone pCF6. Since the 3.8-kb mRNA was detected with clone pCF6 but not with clone pCF5, the 5 (20) .
SI nuclease analysis. Northern blot analysis indicated that the 5' terminus of the 3.8-kb mRNA was positioned within clone pCF6. Indeed, the DNA sequence of pCF6 (19) revealed CCAAT and TATA boxes and a possible cap site within nucleotides 538 to 889 (Fig. 1) . To determine more precisely the transcription start site of the 3.8-kb mRNA, we used S1 nuclease analysis. Clone pCF6 was digested with isolated from mock-infected or EHV-1-infected cells at late times of infection. The DNA-RNA hybrids were subjected to digestion with Si nuclease, and the protected fragments were analyzed on a 6% urea sequencing gel. Two Siresistant fragments of 166 and 115 nucleotides were observed when 10-h-postinfection RNA was used (Fig. 4A,  lane 3) . The 166-nucleotide fragment corresponds to the size of the probe and indicates full protection of the probe by the 5.5-kb transcript. The partially protected fragment of 115 nucleotides (Fig. 4A, lane 3) maps the 3.8-kb mRNA transcription initiation site 6 nucleotides downstream of the predicted cap site at nucleotide 594. These data indicate that transcription initiation of the 3.8-kb mRNA occurs 34 nucleotides downstream of the TATA box (position 561) and 68 nucleotides upstream of the second in-frame ATG (position 661) of the gD ORF. Thus, these findings suggest that the 3.8-kb mRNA encodes the gD gene product and that cisacting transcriptional regulatory elements located upstream of the gD mRNA cap site direct expression of the gD gene.
The assignment of the gD transcription start site at nucleotide 594 by Si nuclease analysis suggests that the CCAAT and TATA boxes located in clone pCF6 are important in transcription of the gD gene. However, CCAAT-and TATAlike elements map within clone pCF5 (nucleotides 243 and 328, respectively [ Fig. 1]) ; therefore, it was important to determine whether an additional transcriptional start site for the gD mRNA exists. Si nuclease analysis with clone pCF5 labeled at the 5' terminus of the HpaI site (position 538) was used as the hybridization probe. The approximately 538-nucleotide fragment observed in analyses with late RNA corresponds to the full-length probe protected by the 5.5-kb mRNA (Fig. 4B) . No partially protected fragment was observed, indicating that transcription initiation does not occur within clone pCF5. Thus, these data indicate that the gD transcript initiates solely at position 594 and encodes a polypeptide of 392 amino acids whose synthesis initiates at the second in-frame ATG.
Northern blot analysis revealed that the 3' terminus of the 1.7-kb mRNA was located within clone pCF6. Analysis of the DNA sequence revealed a consensus polyadenylation signal sequence at position 649 (AATAAA [52] ), a CA dinucleotide at position 672 that may serve as the site of cleavage, and a G+T-rich region (nucleotides 692 through 703) similar to that known to bind components of the cleavage-polyadenylation complex (66) . When clone pSZ-4 was 3' end labeled at the KpnI site (Fig. SA) and used as a probe in S1 nuclease analysis, a single Si-resistant fragment of approximately 696 nucleotides was observed with late RNA but no protected fragments were observed with mockinfected RNA (Fig. SA) . These data localize the 3' terminus of the 1.7-kb mRNA to within 25 nucleotides of the predicted cleavage site at position 672.
The 3' termini of the 5. SB, lanes 2 and 3, respectively) . This fragment maps the 3' termini of both the 5.5-and 3.8-kb mRNAs to lie within the TR at position 4091, or 6 nucleotides downstream of the predicted CA dinucleotide cleavage site. Recently, the 3' terminus of the 1.2-kb IR6 mRNA (transcribed from both inverted repeats [IRs] ) and the 3' terminus of the 2.3-kb US2 mRNA (transcribed from the Us into the IR) were localized to sequences within the internal IR identical to sequences within the TR used for the termination of the 5.5-and 3.8-kb mRNAs (3) (see above). Therefore, two families of 3'-coterminal mRNAs use this termination site within the IRs. One family consists of the 2.3-kb mRNA of the US2 gene and the 1.2-kb mRNA of the diploid IR6 gene, which terminate within the IR, while the second family includes the 5.5-kb, 3.8-kb (gD), and 1.2-kb (IR6) mRNAs which terminate within the TR. The 360-nucleotide S1-resistant fragment observed with early RNA (Fig. 5B, lane 2) results from partial protection of the probe by the 1.2-kb IR6 transcript, since this mRNA is the only species of the 3'-coterminal families that is present at significant levels during early times of infection (3, 22, 23) .
Identification of the EHV-1 gD gene product. The protein product of the gD gene was investigated by using gD-specific antibodies directed to synthetic peptides that correspond to immunogenic domains predicted from computer analysis of the gD amino acid sequence (19) . A 19-mer representing amino acids 4 through 22 of the mature polypeptide and a 20-mer corresponding to residues 267 through 285 were coupled to keyhole limpet hemocyanin, and the peptidecarrier conjugates were used to immunize rabbits. Peptidespecific antibodies present in rabbit sera were readily detected by dot blot analysis and were purified by affinity chromatography (data not shown). In Western blot analyses of purified EHV-1 virions (Fig. 6A) (Fig. 6A, lanes 3 and  6) . Western blot analysis was also used to identify gD polypeptides present in EHV-1-infected cells harvested at late times of infection (12 h postinfection [ Fig. 6B] ). Both the anti-19-mer (Fig. 6B, lane 1) and the anti-20-mer (data not shown) antibodies failed to react with proteins present in mock-infected cells. In contrast, both peptide-specific antibodies reacted with the 55-kDa protein as well as two additional polypeptides of 58 and 47 kDa present in infected cells (Fig. 6B, lane 2) .
Identification of an EHV-1 gD neutralization epitope. gDspecific antibodies were tested for their ability to neutralize virus by incubating each antibody with infectious EHV-1 and subsequently determining the capacity of the virus to (68) , and ['"I]iododeoxycytidine was used as the virus-specific TK substrate. Cells infected with untreated virus and cells infected with virus preincubated with preimmune serum showed similar levels of TK activity over a range of multiplicities of infection (Fig. 7A) . TK levels in cells infected at a multiplicity of 10 PFU per cell with untreated virus or virus incubated with preimmune serum were approximately fivefold greater than those in mockinfected cells. Incubation of virus with anti-19-mer serum prior to infection at a multiplicity of infection of 10 PFU per cell resulted in a greater than twofold reduction in TK activity compared with TK levels induced by untreated virus or virus incubated with preimmune serum. In contrast to these findings for the anti-19-mer serum, no evidence of neutralizing activity was obtained for the anti-20-mer serum (data not shown). As a positive control for neutralization, virus was preincubated with anti-EHV-1 virion serum previously shown to have potent neutralizing activity (61) . This antiserum caused a reduction in TK levels equivalent to the reduction observed by the anti-19-mer serum.
To verify that the anti-19-mer serum has neutralizing activity and to determine whether this activity is complement independent, we performed plaque reduction assays by preincubating approximately 3,000 PFU of EHV-1 with serial dilutions of anti-19-mer serum that was either untreated or heated at 56°C for 1 h to inactivate complement. As shown in Fig. 7B , the anti-19-mer serum achieved 99% inhibition of plaque formation at a serum titer of 80 relative to preimmune serum. Even at a serum titer of 1,280, approx- (61), and anti-19-mer serum (0). At 16 h after infection the monolayers were harvested and cell lysates were assayed for virus-specific TK activity (DPM; y axis) by quantitation of the phosphorylation of
[1251]iododeoxycytidine (68) . Each determination represents the average of three infected-cell cultures, each of which was assayed in triplicate. (B) Virus neutralization as determined by reduction of EHV-1 plaque formation. Duplicate samples of preimmune serum or anti-19-mer serum were either untreated or heated at 56°C for 1 h to inactive complement (C' inactivated). EHV-1 (3,000 PFU) was incubated with twofold dilutions of either preimmune serum or anti-19-mer serum for 1 h at 37°C. The number of infectious virions remaining after incubation was measured by plaque assays performed in triplicate. The data are presented as percent inhibition of plaque formation, calculated relative to the number of plaques obtained with virus incubated with phosphate-buffered saline.
imately 50% of infectious virus was neutralized. Essentially identical levels of neutralization were obtained with either untreated or heated antisera, demonstrating that complement is not necessary for virus neutralization mediated by the anti-19-mer serum. Similar assays performed with the anti-20-mer serum revealed that it lacked neutralizing activity, confirming the results obtained by the TK assay method. Overall, these results show that an EHV-1 neutralization epitope maps at residues 4 through 22 of gD. A diagram summarizing key elements of the gD gene and polypeptide is shown in Fig. 8 , and the domains of gD that are represented by the 19-mer and 20-mer synthetic peptides are indicated.
DISCUSSION
Previously, DNA sequence analysis of the Us of EHV-1
KyA identified the EHV-1 gD and US9 genes and revealed a deletion of 3,859 bp of unique sequences between these genes (19, 20) . In the present study, the gD mRNA was identified and characterized and the gD gene product was shown to be present in virions and to harbor a continuous neutralization epitope within residues 4 to 22. Northern blot analyses revealed three mRNAs (5.5, 3.8, and 1.7 kb) that overlap the gD coding sequences and are transcribed in the same direction as the gD ORF. The 3.8-kb mRNA was shown to be a member of the late (beta-gamma) kinetic class and was assigned as the gD mRNA on the basis of several lines of evidence. (i) The 3.8-kb mRNA overlaps the gD coding sequences, and the 5' terminus of this transcript is in close proximity to the gD ORF. The 5' terminus of the 3.8-kb mRNA was localized 68 nucleotides upstream of the second in-frame methionine of the gD ORF, such that translation would yield a 392-amino-acid polypeptide that possesses a signal sequence at the amino terminus (19 (44) , is gD and is present in EHV-1 virions of the AB1 strain as a 60-kDa glycoprotein. Monoclonal antibodies generated to virion gD were shown to possess neutralizing activity. However, the locations of the reactive epitopes were not identified, and it is not known whether any of these epitopes correspond to the neutralization epitope mapped in this report. Studies with glycanases and inhibitors of glycosylation showed that the glycosylation of gD involved mainly N-linked oligosaccharides (65). Love et al. (36) used antibodies raised to an EHV-1 gD fusion product expressed in Escherichia coli to identify the gD gene product in virions and infected cells.
The 19-mer and 20-mer peptides represent EHV-1 gD continuous antigenic sites that align very closely with continuous epitopes of HSV-1 gD recognized by monoclonal antibodies assigned to groups VII and II, respectively (39) . The EHV-1 anti-19-mer antibody recognizes residues 4 through 22 of EHV-1 gD, whereas the HSV-1 group VII epitopes lie within residues 1 through 23 of HSV-1 gD. Similarly, the EHV-1 anti-20-mer antibody binds to residues 267 through 285 of EHV-1 gD, whereas HSV-1 group II monoclonal antibodies react with amino acids located within residues 264 through 287 of HSV-1 gD. Homology between these continuous antigenic domains of EHV-1 gD and HSV-1 gD is limited, and neither the anti-19-mer nor the anti-20-mer antibody reacts with HSV-1 gD in immunoblotting experiments (data not shown). Group VII monoclonal antibodies neutralize HSV-1 infectivity, reduce plaque size, and inhibit syncytium formation (38) . Immunization of animals with peptides containing the antigenic targets of group VII monoclonal antibodies elicits virus-neutralizing antibodies (7) and protects mice from lethal HSV-1 challenge (13).
The EHV-1 anti-19-mer serum was shown to neutralize virus in cell culture; however, it remains to be determined whether immunization with the 19-mer peptide will afford protection to a lethal EHV-1 challenge, for example, in the hamster-EHV-1 model.
The analysis of gD-negative mutants of HSV-1, pseudorabies virus, and bovine herpesvirus type 1 has demonstrated that the gD class of glycoproteins is essential for virus penetration into target cells (17, 18, 31, 33, 40, 47, 53) . Complement-independent virus neutralization exhibited by the anti-19-mer serum implicates a similar role for EHV-1 gD in virus entry. Indeed, the recent findings of Whittaker et al. (65) demonstrate that monoclonal antibodies to gD prevent EHV-1 penetration into rabbit kidney cells. The colocalization of two continuous antigenic domains within the EHV-1 and HSV-1 gD polypeptides, as well as the conservation of cysteine residues (19) known to be requisite for proper conformation of HSV-1 gD (67), suggests similarities in structure and function for these two viral glycoproteins.
